Table 1.
miRNA | CTRL (n = 20) | Liver Pathologies (n = 77) | HCV (n = 21) |
PBC (n = 10) |
PSC (n = 6) |
ALD (n = 20) |
AIH (n = 20) |
All Samples (n = 97) |
---|---|---|---|---|---|---|---|---|
hsa-miR-27a-3p | −0.591 | −0.251 | −0.156 | −0.417 | −0.829 | 0.174 | −0.335 | −0.301 * |
hsa-miR-27b-3p | −0.107 | 0.003 | 0.339 | 0.150 | −0.200 | −0.039 | 0.102 | 0.092 |
hsa-miR-29a-3p | −0.128 | −0.095 | 0.042 | −0.533 | −0.543 | 0.223 | −0.137 | 0.020 |
hsa-miR-29b-3p | −0.152 | −0.031 | −0.027 | −0.100 | −0.486 | 0.167 | 0.135 | −0.163 |
hsa-miR-29c-3p | −0.099 | −0.184 | −0.129 | −0.733 | −0.543 | 0.062 | −0.480 | −0.186 |
hsa-miR-145-5p | −0.475 | −0.166 | −0.005 | 0.533 | −0.543 | 0.069 | −0.346 | −0.253 |
hsa-miR-320a-3p | −0.209 | −0.053 | −0.048 | 0.333 | −0.714 | 0.463 | −0.368 | 0.049 |
hsa-miR-324-5p | −0.412 | −0.123 | −0.223 | 0.583 | −0.486 | 0.089 | −0.348 | −0.160 |
hsa-miR-342-3p | 0.015 | −0.269 | −0.252 | 0.250 | −0.314 | −0.323 | −0.280 | −0.310 * |
hsa-miR-374a-5p | −0.379 | −0.234 | −0.323 | −0.617 | −0.486 | 0.107 | −0.437 | −0.312 * |
hsa-miR-374b-5p | −0.436 | −0.195 | −0.075 | −0.100 | −0.600 | 0.045 | −0.628 | −0.173 |
hsa-miR-376a-3p | −0.131 | −0.182 | −0.319 | 0.317 | −0.486 | −0.003 | −0.391 | −0.145 |
hsa-miR-425-5p | −0.286 | −0.139 | 0.000 | 0.200 | −0.600 | −0.018 | −0.234 | −0.045 |
hsa-miR-495-3p | 0.083 | −0.219 | −0.229 | 0.350 | −0.257 | −0.077 | −0.503 | −0.193 |
hsa-miR-590-3p | −0.189 | −0.126 | −0.209 | −0.833 | −0.086 | 0.045 | −0.292 | −0.124 |
hsa-miR-605-5p | −0.042 | −0.198 | 0.065 | −0.167 | −0.371 | −0.531 | −0.257 | −0.090 |
Significant negative correlations (p < 0.05) are marked with bold font; * correlation significant after application of Bonferroni correction.